8-K: Tenaya Therapeutics' TN-201 Trial on FDA Clinical Hold

The FDA has placed a clinical hold on Tenaya Therapeutics' MyPEAK-1 trial for TN-201, requesting protocol amendments for patient monitoring and immunosuppression management.

Summary

• The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Tenaya Therapeutics, Inc.'s MyPEAK™-1 Phase 1b/2a clinical trial.
• The trial is evaluating TN-201 for MYBPC3-associated hypertrophic cardiomyopathy.
• The FDA requested an amendment to the protocol, primarily to standardize patient monitoring and immunosuppression regimen management across trial sites.
• This request followed proactive correspondence with the FDA regarding future plans for the TN-201 program.
• The decision is based on data previously reviewed by the independent Data Safety Monitoring Board (DSMB) in summer 2025.
• The DSMB had concluded that TN-201 had an acceptable safety profile, allowing enrollment of expansion cohorts at 3E13 vg/kg (Cohort 1) or 6E13 vg/kg (Cohort 2) dose levels.
• TN-201 has been generally well tolerated, with no new meaningful safety events reported since the DSMB review.
• Tenaya is collaborating with the FDA to resolve the hold and plans to resume dosing once protocol changes are implemented.
• The company does not expect this action to impact data milestones or development timelines for TN-201.

Sentiment

Score: 4

Explanation: The clinical hold is a negative event, but the stated reason (protocol standardization rather than new safety issues) and the company's expectation of no impact on timelines mitigate the severity. The DSMB's prior positive safety assessment also provides some reassurance.

Positives

• The clinical hold is primarily due to a request for protocol amendments related to standardization of patient monitoring and immunosuppression, rather than new adverse safety events.
• The independent Data Safety Monitoring Board (DSMB) concluded in summer 2025 that TN-201 had an acceptable safety profile, allowing enrollment of expansion cohorts.
• TN-201 has been generally well tolerated to date, with no new meaningful safety events associated with it since the DSMB review.
• Management does not expect the clinical hold to impact data milestones or development timelines for TN-201.

Negatives

• The FDA has placed a clinical hold on the MyPEAK™-1 Phase 1b/2a clinical trial for TN-201.
• This action temporarily halts patient dosing until protocol amendments are implemented and the hold is resolved.

Risks

• The expected timing and outcome of regulatory interactions related to the clinical hold on MyPEAK-1.
• The timing and availability of MyPEAK-1 data.
• The potential progress of MyPEAK-1.
• The potential failure of TN-201 to demonstrate safety and/or efficacy in clinical testing.
• The potential for any MyPEAK-1 clinical trial results to differ from preclinical, interim, preliminary or expected results.
• The potential for the FDA to conclude at any time that TN-201 may not have an appropriate risk/benefit profile.
• Ability to enroll and maintain patients in clinical trials, including MyPEAK-1.
• Risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early stage company.
• Continuing compliance with applicable legal and regulatory requirements.
• Ability to raise any additional funding needed to continue product development plans.
• Reliance on third parties.
• Manufacturing, commercialization and marketing capabilities and strategy.
• Loss of key scientific or management personnel.
• Competition in the industry.
• Ability to obtain and maintain intellectual property protection for product candidates.
• General economic and market conditions.

Future Outlook

Management does not expect the FDA's clinical hold to impact data milestones or development timelines for the TN-201 program. The company intends to resume dosing once the requested protocol changes are implemented at trial sites.

Management Comments

• Working swiftly and collaboratively with the FDA to resolve the clinical hold.
• Intends to resume dosing once the protocol changes have been implemented at trial sites.
• Does not expect this action to impact data milestones or development timelines for TN-201.

Industry Context

Clinical holds are a common occurrence in the biotechnology and pharmaceutical industry, particularly for novel gene therapies, as regulatory bodies like the FDA prioritize patient safety and rigorous protocol adherence. The nature of this hold, focusing on standardization of monitoring and immunosuppression rather than new safety concerns, suggests a procedural rather than a fundamental safety issue with the drug itself, which is often viewed more favorably by the market.

Stakeholder Impact

• Shareholders: Potential negative impact on share price due to uncertainty from the clinical hold, though mitigated by the nature of the hold and management's optimistic outlook on timelines.
• Patients: Temporary delay in access to the investigational therapy TN-201 for those awaiting enrollment or dosing in the MyPEAK-1 trial.
• Employees: Continued work on protocol amendments and regulatory interactions.

Next Steps

• Work with the FDA to resolve the clinical hold.
• Implement requested protocol changes at trial sites.
• Resume dosing in the MyPEAK™-1 trial once protocol changes are implemented.

Key Dates

Recommendation

While a clinical hold is a negative development, the specific reasons cited by the FDA (protocol standardization for patient monitoring and immunosuppression) do not indicate new safety concerns with the drug itself, which is a positive. The prior DSMB review also found an acceptable safety profile. Management's assertion that the hold will not impact data milestones or timelines, if accurate, would limit long-term damage. However, any clinical hold introduces uncertainty and potential for unforeseen delays. Investors should hold to monitor the swiftness of resolution and any actual impact on timelines, as well as the company's ability to execute the required protocol amendments.

Keywords

Tenaya Therapeutics, TN-201, FDA clinical hold, MyPEAK-1, hypertrophic cardiomyopathy, MYBPC3, gene therapy, clinical trial, biotechnology, drug development, cardiovascular disease